All Articles

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.

Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/K–mutant stage III melanoma.

The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer.

Our role as oncology nurse and patient navigators is to remove barriers to care for our patients.

Incorporating genetics and genomics in oncology nursing care is key to advancing treatment modalities and care for current and future patients.

The authors present an initiative that aims to develop metrics and analyze the role of oncology nurse navigators in value-based care.

This highly anticipated navigation acuity tool will aid navigators in identifying levels of patient acuity based on the barriers to care, weights of the barriers, and level of patient distress.

Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.